

Thursday, March 16, 2023**EPCG MEMBERS ONLY****16:00 – 18:30****EPCG Meeting**

EPCG Dinner

Sala Camino- Ground Floor

Friday, March 17, 2023**09:00 – 11:00****EPCG Meeting**

Sala Camino- Ground Floor

Friday, March 17, 2023**16:30 – 17:00****Registration and Welcome coffee****Welcome and introductory remarks**

E Zucca

Conference Center - Ground Floor

17:00 – 18:00**Educational Lecture**

17:00 Epigenetic regulation of the germinal center: Implications for lymphoma pathogenesis and treatment

L Pasqualucci

18:00 – 20:15**IELSG Study Discussion 1**

Chair: E Zucca

Primary and Secondary Diffuse Large B-Cell Lymphoma of the Central Nervous System (CNS)

18:00 Report on the EPCG Meeting held on March 16-17, 2023

A Ferreri

18:15 IELSG43 – High-dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS lymphoma – randomized phase III trial (MATRIX) – Study update and results of the first analysis

G Illerhaus

18:30 IELSG45 – Randomized phase II trial on fitness- and comorbidity- tailored treatment in elderly patients with newly diagnosed primary CNS lymphoma (FIORELLA Trial)– Study update

A Ferreri

18:45 – 20:15**Marginal Zone Lymphoma (MZL)**18:45 IELSG39 – International prospective phase II trial addressing the efficacy of first-line *Chloroxydophila psittaci*-eradicating therapy with protracted administration of doxycycline followed by eradication monitoring and antibiotic re-treatment at infection re-occurrence in patients with newly diagnosed Ocular Adnexal Marginal Zone Lymphoma (OAMZL) – Study update and results of the first analysis

M Ponzoni

19:00 IELSG44 – FDG-PET evaluation for marginal zone lymphoma and its prognostic role: an international multicenter retrospective analysis (PIMENTO)

S Luminari

19:15 IELSG47 – MALIBU trial – Phase II study of combination ibrutinib and rituximab in untreated marginal zone lymphomas

A Conconi & C Thieblemont

19:30 IELSG48 – Phase III, interventional, multicentre, open-label, randomized study comparing rituximab plus zanubrutinib to rituximab monotherapy in previously untreated, symptomatic splenic marginal zone lymphoma

D Rossi

19:45 IELSG49 – Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas (MZL)

A Stathis

20:00 IELSG52 - Retrospective study on Nodal MZL (New Project)

MC Pirosa

20:30**Dinner****Saturday, March 18, 2023**

Conference Center Ground Floor

09:00 – 10:40**IELSG Study Discussion 2**

Chair: E Zucca

Primary Mediastinal Lymphoma

09:00 IELSG37 – Randomized study assessing the role of mediastinal radiotherapy after rituximab-containing chemotherapy in Primary Mediastinal B-Cell Lymphoma (PMBCL) - Study update and results of the ongoing analysis

M Martelli

09:15 IELSG37 – Ongoing analysis on the role of PET/CT in PMBCL

L Ceriani

Retrospective Study

09:30 IELSG35 – Primary extranodal lymphoma of female genital tract: final results of the retrospective observational study

S Steffanoni

NK/T-cell Lymphoma

09:45 IELSG50 – Pembrolizumab and radiotherapy for previously untreated patients with limited-stage NK/T cell lymphoma

S Luminari

New Projects

10:00 An international retrospective analysis of RCHOP14 efficacy in PMBL

A Dąbrowska-Iwanicka

10:10 IELSG51 – A future IELSG study in PMBCL?

A Stathis

10:20 Phase II study of R/R extranodal DLBCL

A Stathis & G Nowakowski

10:30 Potential design for a phase II study of frontline MZL treatment

A Conconi

10:40 – 11:00**Coffee Break****11:00 – 12:00****General Assembly**

Chair: F Cavalli

Discussion of administrative issues

IELSG MEMBERS ONLY**12:00****Closing Remarks**

Thank you very much to all our sponsors for supporting this event.

Gold



Bronze



IELSG Annual Meeting 2023
March 17-18, 2023 – Stresa (Italy)



Hotel La Palma
Conference Center – Gardenia Hall
Corso Umberto I n. 33 - 28838 Stresa



INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP
Foundation for the Institute of Oncology Research
Via Vincenzo Vela, 6 | CH-6500 Bellinzona
Phone +41 58 666 73 21 | E-mail ielsg@ior.usi.ch | www.ielsg.org